Search from 1047 projects:
Eine Studie zu Relatlimab plus Nivolumab in Kombination mit Chemotherapie vs. Nivolumab in Kombination mit Chemotherapie bei Teilnehmern mit nicht-kleinzelligem Lungenkarzinom (NSCLC) im Stadium IV oder bei einem Wiederauftreten.Jul 30, 2021
Diese Studie besteht aus zwei Hauptteilen. In der Schweiz wurde Teil 1 bereits beendet. In Teil 1 werden verschiedene Dosen Relatlimab zusammen mit Nivolumab und Chemotherapie verabreicht, um sicherzustellen, dass die Prüfpräparat-Kombination bei Pat...
Clinical Studies - Jul 30, 2021 - Dec 31, 2026
Project leader: Weindler Susanne
MSD MK1308A-004Jul 3, 2021
Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
Clinical Studies - Jul 3, 2021 - Dec 3, 2022
Project leader: Semela David
Members: Stillhard Roman, Bergamin Irina
Immunoproteasome activity as a predictive marker and therapeutic target in hematological malignanciesJul 1, 2021
Fundamental Research - Jul 1, 2021 - Dec 31, 2021
Project leader: Besse Andrej
Members: Kraus Marianne, Besse Lenka
SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase il trialJun 24, 2021
Standard of care for Extensive-Stage Disease (ED) Small Cell Lung Cancer (SCLC) as first-line treatment is 4 to 6 cycles of platinum based chemotherapy (carboplatin or cisplatin) in combination with etoposide. However, the outcome of the disease rema...
Clinical Studies - Jun 24, 2021 - Jun 28, 2027
Project leader: Früh Martin
ALFA ROMEOJun 23, 2021
Atrial fibrillation before and after patent foramen ovale closure study This is a prospective, multicenter, single-arm, observational study assessing the incidence, predictors and prognostic impact of AF occurring before (monitoring phase A) or afte...
Clinical Studies - Jun 23, 2021 - Jun 23, 2025
Project leader: Weilenmann Daniel
Members: Schneider Irene
SWISS-AF Control GroupJun 17, 2021
Contemporary findings from the ongoing Swiss-AF cohort study (2’415 patients with atrial fibrillation (AF) enrolled, 1’760 patients with available brain imaging) showed that patients with AF have a high burden of cerebral infarcts and other brain les...
Clinical Studies - Jun 17, 2021 - Jun 17, 2025
Project leader: Ammann Peter
Members: Fink Karin
Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trialJun 8, 2021
Despite advances in the clinical care of patients with DLBCL and in understanding the biology of this disease, cure rates have remained the same since the introduction of rituximab to CHOP chemotherapy, and RCHOP chemoimmunotherapy remains the standa...
Clinical Studies - Jun 8, 2021 - Dec 31, 2030
Project leader: Hitz Felicitas
Application of smart sensor insoles for assessment of gait parameters and correlation to patient-reported outcomes in hip arthroplasty patientsJun 1, 2021
Gait parameters like gait velocity, stride length, cadence or load symmetry contribute to a successful outcome after total hip arthroplasty (THA) and can be addressed through targeted physiotherapeutic training programs. Instrumented gait analysis i...
Fundamental Research - Jun 1, 2021 - Jun 30, 2025
Project leader: Ladurner Andreas
Members: Giesinger Karlmeinrad
Analysis of the maturation of the peripheral nervous system in neonates, infants and children using high-resolution ultrasound imagingJun 1, 2021
During early childhood nerve conduction velocity (NCS) increases from 20m/s at the time of birth to almost adult values of 50m/s at two years of age. How this increase in NCS is correlated to the structural maturation of the peripheral nerves is unkn...
Clinical Studies - Jun 1, 2021 - Jun 1, 2023
Members: Broser Philip
SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castra-tion-resistant prostate cancerMay 28, 2021
Background: Docetaxel, a semi-synthetic analogue of paclitaxel, is one of the most widely used human anti-cancer agents. Docetaxel and paclitaxel belong to a group of cytotoxic agents called tax-anes. Docetaxel has been marketed worldwide by Sanofi-A...
Clinical Studies - May 28, 2021 - Jun 9, 2023
Project leader: Fischer Stefanie
Pilot study on cognitive and social function measures for early detection of progressive neurocognitive disorders in SwitzerlandMay 12, 2021
Clinical Studies - May 12, 2021 - Sep 15, 2022
Project leader: Felbecker Ansgar
Profiling of quitting trajectories during smoking cessation attempt (SMOKEPROFILE-Study)May 1, 2021
The study hypothesis is twofold. First, we hypothesize that investigating daily tobacco consumption of smokers attempting to quit can be used to characterize clinically relevant quitting trajectories which can be used to predict quitting success. Our...
Fundamental Research - May 1, 2021 - Dec 30, 2023
Project leader: Baty Florent
Members: Brutsche Martin, Bösch Maximilian, Pohle Susanne
Comparison of the effect of outdoor eccentric versus indoor concentric exercise training on physical capacity and qualityof-life in patients with advanced COPD (DOWNHILL-study)May 1, 2021
Patients with chronic obstructive pulmonary disease (COPD) often suffer from cardio-pulmonary limitations, which makes them avoid exercise training. However, exercise training is explicitly recommended for COPD patients as physical activity (PA) is k...
Fundamental Research - May 1, 2021 - Apr 30, 2023
Project leader: Bösch Maximilian
Members: Baty Florent, Brutsche Martin, Benz Gabriel
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Dif-fuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic LeukemiaApr 22, 2021
Aclabrutinib wird in Kombination mit KRT 232 bei R/R CLL und de novo R/R DLBCL jeweils TP 53 WT und BTK naiv eingesetzt. Initial Dosisescalations-stufe (Ib), anschlies-send Phase-II mit RP2D. Primärer Endpunkt: Dosisfin-dung/ Safety ; Efficacy in Ph...
Clinical Studies - Apr 22, 2021 - May 20, 2030
Project leader: Hess Dagmar
Members: Jörger Markus, Hitz Felicitas, Fischer Stefanie
Bayer 20324Apr 14, 2021
TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the majori...
Clinical Studies - Apr 14, 2021 - Apr 21, 2021
A multicenter, non-randomized, open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and characterize its safety, tolerability, pharmacokinetics and preliminiary anti-tumor activity in patients with advanced solid tumorsApr 14, 2021
BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren mit genetischen Alterationen von ATM.
Clinical Studies - Apr 14, 2021 - Feb 21, 2022
Project leader: Jörger Markus
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinibApr 14, 2021
TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the ma...
Clinical Studies - Apr 14, 2021 - Dec 31, 2025
Project leader: Jörger Markus
DiabetescoachApr 1, 2021
Personal Health Coaching für Patient*innen mit Diabetes Typ 2
Clinical Studies - Apr 1, 2021 - Dec 31, 2030
Project leader: Bilz Stefan
Members: Räss Andrea, Grillmayr Victoria
MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)Mar 17, 2021
The rationale for this study comes from preclinical models, in which lenvatinib decreased the tumor-associated macrophage (TAM) population, which is known as an immune-regulator in the tumor microenvironment. The decrease in TAM population was accomp...
Clinical Studies - Mar 17, 2021 - May 7, 2030
Project leader: Fischer Stefanie
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentMar 15, 2021
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical Studies - Mar 15, 2021 - Apr 7, 2030
Project leader: Silzle Tobias
Members: Driessen Christoph, Fehr Martin, Hitz Felicitas, Lehmann Thomas